| Genomic hallmarks of localized, non-indolent prostate cancer M Fraser, VY Sabelnykova, TN Yamaguchi, LE Heisler, J Livingstone, ... Nature 541 (7637), 359-364, 2017 | 593 | 2017 |
| Widespread and functional RNA circularization in localized prostate cancer S Chen, V Huang, X Xu, J Livingstone, F Soares, J Jeon, Y Zeng, JT Hua, ... Cell 176 (4), 831-843. e22, 2019 | 344 | 2019 |
| High frequency of MAGE‐A4 and MAGE‐A9 expression in high‐risk bladder cancer A Bergeron, V Picard, H LaRue, F Harel, H Hovington, L Lacombe, ... International Journal of Cancer 125 (6), 1365-1371, 2009 | 118 | 2009 |
| MAGE‐A9 mRNA and protein expression in bladder cancer V Picard, A Bergeron, H LaRue, Y Fradet International journal of cancer 120 (10), 2170-2177, 2007 | 58 | 2007 |
| Genome-wide germline correlates of the epigenetic landscape of prostate cancer KE Houlahan, YJ Shiah, A Gusev, J Yuan, M Ahmed, A Shetty, ... Nature medicine 25 (10), 1615-1626, 2019 | 55 | 2019 |
| Translating a prognostic DNA genomic classifier into the clinic: retrospective validation in 563 localized prostate tumors E Lalonde, R Alkallas, MLK Chua, M Fraser, S Haider, A Meng, J Zheng, ... European urology 72 (1), 22-31, 2017 | 51 | 2017 |
| Omega‐3 fatty acids decrease prostate cancer progression associated with an anti‐tumor immune response in eugonadal and castrated mice N Gevariya, M Besançon, K Robitaille, V Picard, L Diabaté, A Alesawi, ... The Prostate 79 (1), 9-20, 2019 | 39 | 2019 |
| Cancer-testis antigen expression in bladder cancer Y Fradet, V Picard, A Bergeron, H LaRue Progres en Urologie 15 (6), 1303, 2005 | 25 | 2005 |
| Cancer-testis antigen expression in bladder cancer Y Fradet, V Picard, A Bergeron, H LaRUE Prog Urol 16 (4), 421-8, 2006 | 17 | 2006 |
| Combining antiandrogens with immunotherapy for bladder cancer treatment M Besançon, T Gris, FH Joncas, V Picard, A Bergeron, Y Fradet, P Toren European Urology Open Science 43, 35-44, 2022 | 11 | 2022 |
| Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression B Vittrant, A Bergeron, OE Molina, M Leclercq, XP Légaré, H Hovington, ... Oncoimmunology 9 (1), 1851950, 2020 | 9 | 2020 |
| Cancer Antigen Mage-A9 and Uses Thereof A Bergeron, V Picard, H Larue, Y Fradet US Patent App. 12/093,617, 2009 | 6 | 2009 |
| CAnAdIAn BlAdder CAnCer ForUm 2023 A Bergeron, V Picard, M Besançon, LD MacDonald, K Mody, A Hilchie, ... CUAJ 17 (3), 2023 | | 2023 |
| MP06-13 TARGETING THE ANDROGEN RECEPTOR AXIS TO IMPROVE RESPONSE TO BLADDER CANCER IMMUNOTHERAPY T Gris, M Besançon, FH Joncas, V Picard, A Bergeron, Y Fradet, P Toren The Journal of Urology 207 (Supplement 5), e82, 2022 | | 2022 |
| DPX-SurMAGE, a novel dual-targeted immunotherapy for bladder cancer, induces target-specific T cells with a favorable safety profile in preclinical model V Picard, V Kaliaperumal, F Gaignier, M Besancon, Y Bramhecha, ... MOLECULAR CANCER THERAPEUTICS 20 (12), 2021 | | 2021 |
| Abstract LBA030: DPX-SurMAGE, a novel dual-targeted immunotherapy for bladder cancer, induces target-specific T cells with a favorable safety profile in preclinical model V Picard, V Kaliaperumal, F Gaignier, M Besançon, Y Bramhecha, ... Molecular Cancer Therapeutics 20 (12_Supplement), LBA030-LBA030, 2021 | | 2021 |
| MP70-17 DECIPHERING THE EFFECTS OF OMEGA-3 FATTY ACID SUPPLEMENTS ON PROSTATE CANCER G Lachance, N Geveriya, K Robitaille, A Bergeron, V Picard, M Leclerc, ... The Journal of Urology 199 (4S), e941-e941, 2018 | | 2018 |
| Abstract A28: Mutational landscape of TP53 in localized prostate cancer O Mahamud, MLK Chua, S Supiot, E Lalonde, AD Pra, A Berlin, M Orain, ... Molecular Cancer Research 15 (4_Supplement), A28-A28, 2017 | | 2017 |
| CHAPITRE 4: PD-1 and LAG-3 dual inhibition for the immunotherapy of bladder cancer F Gaignier, M Besançon, V Picard, J Caron, D St-Onge, M Leclercq, ... Immunothérapie non-spécifique du cancer de la vessie: développement de …, 2017 | | 2017 |
| CHAPITRE 5: Inhibition of Androgen Receptor Synergizes with PD-1 Blockade to Enhance Antitumor Effect Against Bladder Cancer M Besançon, R Merand, A Bergeron, V Picard, P Toren, Y Fradet Immunothérapie non-spécifique du cancer de la vessie: développement de …, 2017 | | 2017 |
Yves FradetUniversité LavalVerified email at crhdq.ulaval.ca
